Australia Stock Alert

AUSTR

CLOSING UPDATE: CSL decreases gains by 0.2%, led Pharmaceuticals & biotechnology sector higher January 19, 2018 16:00:00 AEST

NEWS BITES - AUSTRALIA

This is an end of day Alert, produced after today's Australian market close. It concludes the BSS News Bites intra-day Alert series (summaries below).

CSL, Australia's largest pharmaceuticals & biotechnology company by market capitalisation, has increased 1.1% to trade at $A143.93 vs. the Pharmaceuticals & biotechnology sector which strengthened 134.8 points (or 0.8%) to 17,609.7. Representing a weighting of about 88.6% of the sector, the stock accounted for the gain. Trading volume was 92% of average at the end of the day. Compared with the All Ordinaries Index which fell 24.7 points (or 0.4%) in the day, this represented a relative price increase of 1.5%.

Technical indicators complementing today's significant uptrend:

+ The positive 0.2 MACD (Moving Average Convergence Divergence) indicator suggests a bullish signal.

+ The 3.6% discount to 12-month high of $A149.30 against the 32.6% premium to 12-month low of $A108.51 suggests the stock continues to push for new highs.

+ In the last three months the stock has hit a new 52-week high eight times, pointing to a significant uptrend.

+ The price increased 1.5% in the last week and 1.0% in the last month.

Fundamental measures by comparison with the sector average [in brackets] indicate:

Undervaluation:

+ Return on Equity 42.3% [19.4%]

+ Return on Assets 14.7% [8.6%]

+ Return on Capital Employed 23.7% [14.4%]

Other Bullish Signals include:

+ Interest cover is less leveraged at 19.8 times.

+ Total Liabilities/EBITDA of 3.3 is comfortably below the Joseph Piotroski benchmark of <5.

+ Net profit margin has averaged 21.6% in the last 3 years. This is considered superior and suggests a high margin of safety.

+ As per the Du Pont analysis, Return on Equity is high at 42.3%.

Note

Bearish Signals:

Tobin's Q Ratio is 5.7. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

Fundamental measures by comparison with the sector average [in brackets] indicate:

Overvaluation:

Year-on-Year Earnings Growth of 9.6% [11.4%]

TODAY'S ALERTS

Afternoon Alert: CSL increases 1.2%, leads S&P/ASX 200 Health Care index higher

January 19, 2018 13:00:00 AEST

CSL Limited (ASX:CSL) has increased 1.2% to trade at $A144.16 vs. the S&P/ASX 200 Health Care index which strengthened 90.5 points (or 0.4%) to 24,627.9. Representing a weighting of about 47.7% of the index, the stock accounted for the gain.

Morning Alert: CSL increases 1.3%, leads S&P/ASX 200 Health Care index higher

January 19, 2018 11:00:00 AEST

CSL Limited (ASX:CSL) has increased 1.3% to trade at $A144.24 vs. the S&P/ASX 200 Health Care index which strengthened 83.8 points (or 0.3%) to 24,621.2. Representing a weighting of about 47.7% of the index, the stock accounted for the gain.

RECENT ALERTS

CLOSING UPDATE: CSL decreases gains by 0.01%, led S&P/ASX 200 Health Care index higher

January 15, 2018 16:00:00 AEST

CSL, Australia's largest pharmaceuticals & biotechnology company by market capitalisation, has increased 0.8% to trade at $A143.0 vs. the S&P/ASX 200 Health Care index which strengthened 90.9 points (or 0.4%) to 24,531.9. Representing a weighting of about 47.5% of the index, the stock accounted for the gain. Trading volume was 69% of average at the end of the day. Compared with the All Ordinaries Index which rose 9.7 points (or 0.2%) in the day, this represented a relative price increase of 0.7%.

Afternoon Alert: CSL increases 0.8%, leads S&P/ASX 200 Health Care index higher

January 15, 2018 13:00:00 AEST

CSL Limited (ASX:CSL) has increased 0.8% to trade at $A143.01 vs. the S&P/ASX 200 Health Care index which strengthened 90.9 points (or 0.4%) to 24,531.9. Representing a weighting of about 47.5% of the index, the stock accounted for the gain.

CSL Limited (AU:CSL; ASX:CSL; AX:CSL)

ISIN: AU000000CSL8

PermID: 4295856855

Source: www.BuySellSignals.com